Management of nocturnal enuresis with a vasopressin analogue.

Abstract

The effect of 20 micrograms. desaminocysteine-D-arginine vasopressin intranasally on childhood nocturnal enuresis was studied in a randomized double-blind cross-over series of 54 children. The wetting was significantly less frequent during the 2, 3-week periods on desaminocysteine-D-arginine vasopressin than during placebo periods, or during periods without any treatment. The effect of desaminocysteine-D-arginine vasopressin was reproducible and the efficacy of desaminocysteine-D-arginine vasopressin depended on the frequency of wetting before treatment. After discontinuation of the short treatment enuresis recurred immediately. No side effects were noted. We conclude that desaminocysteine-D-arginine vasopressin may well be used in the management of childhood enuresis, especially in situations when an immediate effect is desirable.

• Authors: P Terho, M Kekomäki
• Journal: The Journal of urology (J Urol) Vol. 131 Issue 5 Pg. 925-7 (May 1984) ISSN: 0022-5347 [Print] United States
• PMID: 6368874 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Arginine Vasopressin
• Deamino Arginine Vasopressin

Topics

• Adolescent
• Arginine Vasopressin (therapeutic use)
• Child
• Clinical Trials as Topic
• Deamino Arginine Vasopressin (adverse effects, therapeutic use)
• Double-Blind Method
• Enuresis (drug therapy)
• Humans